FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Breen Michael Martin
2. Date of Event Requiring Statement (Month/Day/Year)
01/13/2021
3. Issuer Name and Ticker or Trading Symbol
GT Biopharma, Inc. [GTBP]
(Last)
(First)
(Middle)
C/O GT BIOPHARMA, INC., 9350 WILSHIRE BLVD., STE. 203
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

BEVERLY HILLS, CA 90212
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
10% Senior Convertible Debenture 09/07/2018   (1) Common Stock (1) $ 3.4 (1) D  
10% Senior Convertible Debenture 06/23/2020 06/23/2021 Common Stock (2) $ 3.4 (2) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Breen Michael Martin
C/O GT BIOPHARMA, INC.
9350 WILSHIRE BLVD., STE. 203
BEVERLY HILLS, CA 90212
  X      

Signatures

/s/ Michael Martin Bree 11/09/2021
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Reflects a 10% Senior Convertible Debenture in the face amount of $100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis).
(2) Reflects a 10% Senior Convertible Debenture in the face amount of $30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.